Prostate cancer is Australia's most commonly diagnosed cancer. One in six men will be diagnosed by the time they turn 85. Cancers are abnormal groups of cells that grow uncontrollably and start ...

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

SBRT combined with Nexavar improved median OS to 15.8 months versus 12.3 months with Nexavar alone in patients with advanced HCC. Median PFS increased from 5.5 months with Nexavar alone to 9.2 months ...

SBRT and surgery showed similar overall survival in stage I NSCLC, offering a non-invasive option for high-risk surgical patients. Surgery demonstrated better disease-free and recurrence-free survival ...

Prostate cancer relapse treatment could be cut from 35 visits to just five. See how new radiation technology may change your ...

Stereotactic radiation therapy has emerged as a cornerstone in the management of early-stage and locally recurrent non-small cell lung cancer (NSCLC), particularly in patients who are medically ...

SBRT and hypofractionated CRT showed similar effectiveness and low severe side effects in stage 1 NSCLC treatment. SBRT delivers higher radiation doses in fewer sessions, while hypofractionated CRT ...

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing ...

This prospective study included 135 patients (median age, 67 years; 66 women) who underwent MRI-guided SBRT for liver metastases across seven international centres between April 2019 and April 2023.

SBRT involves constructing very compact high-dose volumes in and about the tumor. Tumor position must be accurately assessed throughout treatment, especially for tumors that move with respiration.

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...